Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

MRI-Targeted biopsy matches standard method in prostate cancer detection

NCT ID NCT02050542

Diagnosis Sponsor: Assistance Publique - Hôpitaux de Paris Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether using an MRI to guide prostate biopsies could detect cancer as well as the standard 12-sample systematic biopsy. Researchers enrolled 108 men aged 45-75 with elevated PSA levels and suspicious MRI findings. They compared the cancer detection rates of 3 targeted biopsies guided by MRI-ultrasound fusion against the standard 12-sample approach.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

108 people

The number who actually took part.

Start date

Jun 2014

Finished

Feb 2015

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

45 to 75 years

Sex

Male participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * patient from 45 to 75 years old; * Serum level of PSA \> 4,0 ng / mL; * Multiparametric prostate IRM, performed before inclusion and which confirm the diagnosis of suspected target; * No opposition of the patient notified in the medical record * patient member in a national insurance scheme. Exclusion Criteria: * Previous prostate biopsy; * suspicious digital rectal examination; * serum PSA \> 20,0 ng / mL; * treatment with 5 alpha reductase inhibitor during the last 3 months; * untreated urinary infection

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Prostate cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

neoplasm prostate cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Prostate cancer

Contacts and locations

Locations

  • CHU Cochin

    Paris, 75014, France

  • CHU Grenoble

    Grenoble, 38043, France

  • CHU Pitié salpêtrière

    Paris, 75013, France

  • CHU Toulouse Rangueil

    Toulouse, 31076, France

  • Chu Edouard Herriot

    Lyon, 69437, France

  • Clinique Pasteur

    Toulouse, 31076, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.